The Epoch Times
The Epoch Times
AD
The Epoch Times
Support Us
SHARE
USCourts

Three States Renew Lawsuit Against FDA Over Abortion Pill Regulations

Missouri Attorney General Andrew Bailey said the lawsuit aims to protect women’s health by restoring medical safeguards.
Copy
Facebook
X
Truth
Gettr
LinkedIn
Telegram
Email
Save
Three States Renew Lawsuit Against FDA Over Abortion Pill Regulations
Missouri Attorney General Andrew Bailey testifies before the House Judiciary Committee hearing on the Manhattan District Attorney's Office, on Capitol Hill in Washington on June 13, 2024. Jose Luis Magana/AP Photo
Matthew Vadum
By Matthew Vadum
10/19/2024Updated: 10/20/2024
0:00

Missouri, Idaho, and Kansas renewed their lawsuit against the U.S. Food and Drug Administration (FDA) over the abortion pill mifepristone months after the Supreme Court refused to invalidate approval of the pill.

Access to abortion is a political issue in the current election cycle. Abortion-related initiatives are on the ballot next month in 10 states, including Arizona, Florida, Missouri, and South Dakota.

Matthew Vadum
Matthew Vadum
contributor
Matthew Vadum is an award-winning investigative journalist.
Author’s Selected Articles

Georgia Supreme Court Strikes Down 4 Election Rules Approved by State Election Board

Jun 10, 2025
Georgia Supreme Court Strikes Down 4 Election Rules Approved by State Election Board

Supreme Court to Consider Sentence Reductions for Men Convicted of Armed Robbery

Jun 10, 2025
Supreme Court to Consider Sentence Reductions for Men Convicted of Armed Robbery

Oklahoma Won’t Pursue Death Penalty for Inmate After Supreme Court Reversed Conviction

Jun 10, 2025
Oklahoma Won’t Pursue Death Penalty for Inmate After Supreme Court Reversed Conviction

Supreme Court Declines to Reopen Terrorism Victims’ Lawsuit Over Bank Allegedly Tied to Hamas

Jun 09, 2025
Supreme Court Declines to Reopen Terrorism Victims’ Lawsuit Over Bank Allegedly Tied to Hamas
Save
The Epoch Times
Copyright © 2000 - 2025 The Epoch Times Association Inc. All Rights Reserved.